Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Inhibrx Biosciences

122.06
-4.6400-3.66%
Volume:113.98K
Turnover:13.94M
Market Cap:1.79B
PE:-13.75
High:129.88
Open:124.98
Low:120.62
Close:126.70
52wk High:155.29
52wk Low:26.19
Shares:14.67M
Float Shares:8.64M
Volume Ratio:0.52
T/O Rate:1.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.8768
EPS(LYR):-9.0434
ROE:-1773.60%
ROA:-43.61%
PB:-33.80
PE(LYR):-13.50

Loading ...

OverviewCompanyNewsFilings

Inhibrx says INBRX-106 plus pembrolizumab lifts Phase 2 HNSCC response rate to 44%

Reuters
·
May 11

Inhibrx Reports Interim Phase 2 Data for Inbrx-106 in First-Line Hnscc; Initial Results Demonstrate Potential Costimulatory Benefit Over Pd-1 Monotherapy

THOMSON REUTERS
·
May 11

Inhibrx Biosciences Inc - up to 15-Fold Increase in Systemic T-Cell Expansion With Inbrx-106 Plus Pembrolizumab

THOMSON REUTERS
·
May 11

Inhibrx Biosciences Inc - Three Complete Radiographic Responses Observed With Inbrx-106 Plus Pembrolizumab

THOMSON REUTERS
·
May 11

Inhibrx Biosciences Inc - Inbrx-106 Plus Pembrolizumab Achieves 44.0% Confirmed Orr VS 21.4% With Pembrolizumab Alone

THOMSON REUTERS
·
May 11

Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences

Dow Jones
·
May 09

Inhibrx Biosciences' Shares Up Ahead of Phase 2 Head and Neck Cancer Drug Data

Dow Jones
·
May 09

Inhibrx to webcast interim Phase 2 HexAgon results for INBRX-106 in HNSCC

Reuters
·
May 09

BRIEF-Inhibrx to host webcast presentation to provide clinical update on INBRX-106 HexAgon study in first line HNSCC

Reuters
·
May 09

Inhibrx to Host Webcast Presentation to Provide Clinical Update on Inbrx-106 Hexagon Study in First Line Hnscc

THOMSON REUTERS
·
May 09

A Look At Inhibrx Biosciences (INBX) Valuation After New Ozekibart Data And BLA Submission

Simply Wall St.
·
May 02

Inhibrx initiated with an Outperform at LifeSci Capital

TIPRANKS
·
Apr 24

Why Inhibrx Biosciences (INBX) Is Up 44.3% After Ozekibart Colorectal Cancer Efficacy Update And What's Next

Simply Wall St.
·
Apr 24

Inhibrx Biosciences announces annual shareholder meeting webcast

Reuters
·
Apr 24

A Look At Inhibrx Biosciences (INBX) Valuation After Recent Ozekibart And Chondrosarcoma Trial Updates

Simply Wall St.
·
Apr 23

Small U.S. Stocks Rise; Inhibrx Biosciences Climbs Highest

Dow Jones
·
Apr 23

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Benzinga_recent_news
·
Apr 23

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway

Reuters
·
Apr 23

Inhibrx price target raised to $300 from $150 at Stifel

TIPRANKS
·
Apr 23

Top Midday Stories: GE Vernova Shares Gain on Strong Q1 Earnings, Guidance; Vertiv Lifts Guidance After Q1 EPS, Revenue Beats, Shares Fall

MT Newswires Live
·
Apr 22
More